.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Merck
Cipla
UBS
Boehringer Ingelheim
McKinsey
Baxter
Cerilliant
Colorcon
Medtronic

Generated: December 14, 2017

DrugPatentWatch Database Preview

Claims for Patent: 5,998,367

« Back to Dashboard

Claims for Patent: 5,998,367

Title: Pramlintide pro H-amylin salts and compositions
Abstract:Agonist analogues of amylin and related pharmaceutical compositions, and methods of treatment of diabetes and other insulin-requiring states, as well as methods of treatment of hypoglycemia, are provided.
Inventor(s): Gaeta; Laura S. L. (La Jolla, CA), Jones; Howard (Poway, CA), Albrecht; Elisabeth (San Diego, CA)
Assignee: Amylin Corporation (San Diego, CA)
Application Number:08/892,549
Patent Claims: 1. A pharmaceutically acceptable salt of the peptide ##STR1## said peptide having an intramolecular linkage between the cysteine amino acid residues at positions two and seven and tyrosinamide as the thirty-seventh amino acid residue.

2. A composition comprising a pharmaceutically acceptable salt of the peptide ##STR2## said peptide having an intramolecular linkage between the cysteine amino acid residues at positions two and seven and tyrosinamide as the thirty-seventh amino acid residue, in a pharmaceutically acceptable carrier.

3. A composition comprising an acetate salt of the peptide ##STR3## said peptide having an intramolecular linkage between the cysteine amino acid residues at positions two and seven and tyrosinamide as the thirty-seventh amino acid residue, in a pharmaceutically acceptable carrier.

4. A composition comprising a hydrochloride salt of the peptide ##STR4## said peptide having an intramolecular linkage between the cysteine amino acid residues at positions two and seven and tyrosinamide as the thirty-seventh amino acid residue, in a pharmaceutically acceptable carrier.

5. A composition comprising a trifluoroacetate salt of the peptide ##STR5## said peptide having an intramolecular linkage between the cysteine amino acid residues at positions two and seven and tyrosinamide as the thirty-seventh amino acid residue, in a pharmaceutically acceptable carrier.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Queensland Health
McKinsey
UBS
Mallinckrodt
Teva
Baxter
Cerilliant
QuintilesIMS
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot